U.S. markets closed

Humanigen, Inc. (HGEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6400-0.1300 (-7.34%)
At close: 04:00PM EDT
1.6400 0.00 (0.00%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.7700
Bid1.6400 x 28000
Ask1.6600 x 800
Day's Range1.6200 - 1.8500
52 Week Range1.6200 - 18.6800
Avg. Volume1,404,095
Market Cap115.839M
Beta (5Y Monthly)-1.02
PE Ratio (TTM)N/A
EPS (TTM)-3.1140
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.43
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for HGEN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Humanigen, Inc.
    CDMO: What does Argus have to say about CDMO?AVID BIOSERVICES INC has an Investment Rating of SELL; a target price of $12.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Business Wire

    NIH/NIAID Locks ACTIV-5/BET-B Database

    SHORT HILLS, N.J., June 30, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, confirms that notice was received today from the National Institute of Allergy and Infectious Diseases (NIAID) that they have completed database lock for the Big Effect Trial of lenzilumab (BET-B) being conducted as part of the National Institute

  • Business Wire

    Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom

    SHORT HILLS, N.J., June 16, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced it entered into an agreement with PCI Pharma Services (PCI), a leading integrated global contract development manufacturing organization (CDMO), to provide importation, release and commercialization services in the United Kingdom (UK) for lenzilumab. Under the agreement,

  • Simply Wall St.

    Insiders who purchased this year lose US$14k as Humanigen, Inc. (NASDAQ:HGEN) stock drops to US$2.18

    The recent 16% drop in Humanigen, Inc.'s ( NASDAQ:HGEN ) stock could come as a blow to insiders who purchased US$154k...